These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24678935)

  • 21. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
    Kacperska MJ; Jastrzebski K; Tomasik B; Walenczak J; Konarska-Krol M; Glabinski A
    J Mol Neurosci; 2015 May; 56(1):154-63. PubMed ID: 25487315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease.
    Hara N; Kikuchi M; Miyashita A; Hatsuta H; Saito Y; Kasuga K; Murayama S; Ikeuchi T; Kuwano R
    Acta Neuropathol Commun; 2017 Jan; 5(1):10. PubMed ID: 28137310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA predicts cognitive performance in healthy older adults.
    Gullett JM; Chen Z; O'Shea A; Akbar M; Bian J; Rani A; Porges EC; Foster TC; Woods AJ; Modave F; Cohen RA
    Neurobiol Aging; 2020 Nov; 95():186-194. PubMed ID: 32846274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.
    Dardiotis E; Aloizou AM; Siokas V; Patrinos GP; Deretzi G; Mitsias P; Aschner M; Tsatsakis A
    J Mol Neurosci; 2018 Dec; 66(4):617-628. PubMed ID: 30415446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA: Basic concepts and implications for regeneration and repair of neurodegenerative diseases.
    Saraiva C; Esteves M; Bernardino L
    Biochem Pharmacol; 2017 Oct; 141():118-131. PubMed ID: 28709951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systems approach to neurodegenerative disease biomarker discovery.
    Lausted C; Lee I; Zhou Y; Qin S; Sung J; Price ND; Hood L; Wang K
    Annu Rev Pharmacol Toxicol; 2014; 54():457-81. PubMed ID: 24160693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's Diseases.
    Batistela MS; Josviak ND; Sulzbach CD; de Souza RL
    Int J Neurosci; 2017 Jun; 127(6):547-558. PubMed ID: 27381850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease.
    Guo R; Fan G; Zhang J; Wu C; Du Y; Ye H; Li Z; Wang L; Zhang Z; Zhang L; Zhao Y; Lu Z
    J Alzheimers Dis; 2017; 60(4):1365-1377. PubMed ID: 29036818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of miR-137 in Neurodegenerative Disorders.
    Bodai L; Borosta R; Ferencz Á; Kovács M; Zsindely N
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurodegenerative Disorders Treatment: The MicroRNA Role.
    Ridolfi B; Abdel-Haq H
    Curr Gene Ther; 2017; 17(5):327-363. PubMed ID: 29357791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNAs as biomarkers for clinical studies.
    Pogribny IP
    Exp Biol Med (Maywood); 2018 Feb; 243(3):283-290. PubMed ID: 28914096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging role of circulating microRNAs as biomarkers in autoimmune diseases.
    Zeng L; Cui J; Wu H; Lu Q
    Autoimmunity; 2014 Nov; 47(7):419-29. PubMed ID: 24953646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Universal screening test based on analysis of circulating organ-enriched microRNAs: a novel approach to diagnostic screening.
    Sheinerman KS; Umansky S
    Expert Rev Mol Diagn; 2015 Mar; 15(3):329-38. PubMed ID: 25354444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dysregulation and diagnostic potential of microRNA in Alzheimer's disease.
    Pan Y; Liu R; Terpstra E; Wang Y; Qiao F; Wang J; Tong Y; Pan B
    J Alzheimers Dis; 2016; 49(1):1-12. PubMed ID: 26484912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics.
    Roy B; Lee E; Li T; Rampersaud M
    Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases.
    Baldacci F; Lista S; O'Bryant SE; Ceravolo R; Toschi N; Hampel H;
    Methods Mol Biol; 2018; 1750():139-155. PubMed ID: 29512070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.
    Mushtaq G; Greig NH; Anwar F; Zamzami MA; Choudhry H; Shaik MM; Tamargo IA; Kamal MA
    Med Chem; 2016; 12(3):217-25. PubMed ID: 26527155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers of neurodegenerative disorders: how good are they?
    Rachakonda V; Pan TH; LE WD
    Cell Res; 2004 Oct; 14(5):347-58. PubMed ID: 15538967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases.
    Nayak A; Salt G; Verma SK; Kishore U
    Int Rev Neurobiol; 2015; 121():59-86. PubMed ID: 26315762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases.
    Sheta EA; Appel SH; Goldknopf IL
    Expert Rev Proteomics; 2006 Feb; 3(1):45-62. PubMed ID: 16445350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.